Novo Nordisk, a leading pharmaceutical company, has announced that it will maintain its popular insulin brand, Mixtard, in vial format in the Indian market, even as it discontinues Penfill cartridges. The move comes amidst apprehensions regarding the withdrawal of commonly used insulin products. The decision is part of the company’s strategy to streamline its insulin offerings in response to growing patient needs and to guarantee a consistent drug supply, with a particular emphasis on modern therapies. By prioritizing newer treatments, Novo Nordisk aims to better cater to the evolving healthcare requirements of the Indian population.